--- title: "How Eli Lilly’s Global Vault CRM Rollout At Veeva Systems (VEEV) Has Changed Its Investment Story" type: "News" locale: "en" url: "https://longbridge.com/en/news/296430987.md" description: "Eli Lilly's global rollout of Veeva Vault CRM reinforces Veeva Systems' AI-driven investment narrative, highlighting a shift toward agentic commercial workflows. While this adoption supports revenue growth and recent guidance raises, it also underscores concentration risk among large pharma customers. Analysts project $4.7 billion in revenue by 2029, though some caution on the pace of AI monetization remains." datetime: "2026-08-20T03:42:58.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296430987.md) - [en](https://longbridge.com/en/news/296430987.md) - [zh-HK](https://longbridge.com/zh-HK/news/296430987.md) --- # How Eli Lilly’s Global Vault CRM Rollout At Veeva Systems (VEEV) Has Changed Its Investment Story - Earlier this month, Eli Lilly and Company committed to deploy Veeva Vault CRM globally as part of Veeva’s Vault CRM Suite supporting agentic commercial workflows. - This global rollout by a major pharmaceutical company highlights growing interest in AI-enabled commercial tools like Veeva’s Agentic Call Report to help generate commercial evidence. - We’ll now examine how Eli Lilly’s global Vault CRM commitment could influence Veeva’s investment narrative, especially around AI‑driven commercial execution. This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality. ## Veeva Systems Investment Narrative Recap To own Veeva, you generally need to believe that life sciences will keep standardizing on its cloud platforms and increasingly adopt embedded AI agents across clinical and commercial workflows. Eli Lilly’s global Vault CRM rollout reinforces the AI‑driven execution catalyst in the near term, while also highlighting a key risk: heavier dependence on a concentrated group of large pharma customers whose future budgets and bargaining power could materially influence Veeva’s pricing and growth profile. Among recent developments, Veeva’s June 2026 guidance raise for fiscal 2027 to US$3,635 million to US$3,645 million in revenue stands out. That update, together with accelerating Vault CRM commitments from companies like Merck KGaA and Teva, frames Eli Lilly’s global rollout as part of a broader shift toward Veeva’s AI‑enabled suites, which could matter for how investors think about both the CRM transition catalyst and concentration risk in the commercial business. Yet beneath the optimism around Eli Lilly, investors should still pay close attention to the growing concentration of revenue among top pharma accounts and... Read the full narrative on Veeva Systems (it's free!) Veeva Systems' narrative projects $4.7 billion revenue and $1.4 billion earnings by 2029. This requires 12.4% yearly revenue growth and about a $0.5 billion earnings increase from $941.7 million today. Uncover how Veeva Systems' forecasts yield a $245.48 fair value, in line with its current price. ## Exploring Other Perspectives VEEV 1-Year Stock Price Chart Some of the lowest ranked analysts were expecting only about US$4.5 billion in revenue and US$1.3 billion in earnings by 2029, so compared with today’s AI and Vault CRM momentum, their more cautious view on how quickly Veeva’s AI agents and broader cloud adoption might translate into durable financial outcomes offers you a useful contrast to explore. Explore 12 other fair value estimates on Veeva Systems - why the stock might be worth 34% less than the current price! ## Decide For Yourself Don't just follow the ticker - dig into the data and build a conviction that's truly your own. - A great starting point for your Veeva Systems research is our analysis highlighting 3 key rewards that could impact your investment decision. - Our free Veeva Systems research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Veeva Systems' overall financial health at a glance. ## Curious About Other Options? Every day counts. These free picks are already gaining attention. See them before the crowd does: - Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow. - The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 17 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement. - The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation. _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### **New:** Manage All Your Stock Portfolios in One Place We've created the **ultimate portfolio companion** for stock investors, **and it's free.** • Connect an unlimited number of Portfolios and see your total in one currency • Be alerted to new Warning Signs or Risks via email or mobile • Track the Fair Value of your stocks Try a Demo Portfolio for Free ### Related Stocks - [VEEV.US](https://longbridge.com/en/quote/VEEV.US.md) - [LLY.US](https://longbridge.com/en/quote/LLY.US.md) - [ELIS.US](https://longbridge.com/en/quote/ELIS.US.md) - [LLYX.US](https://longbridge.com/en/quote/LLYX.US.md) - [LLYZ.US](https://longbridge.com/en/quote/LLYZ.US.md) - [ELIL.US](https://longbridge.com/en/quote/ELIL.US.md) - [MRK.DE](https://longbridge.com/en/quote/MRK.DE.md) - [TEVA.US](https://longbridge.com/en/quote/TEVA.US.md) - [NVDA.US](https://longbridge.com/en/quote/NVDA.US.md) - [MSFT.US](https://longbridge.com/en/quote/MSFT.US.md) - [NVD.DE](https://longbridge.com/en/quote/NVD.DE.md) ## Related News & Research - [Why Is Omniab Stock Rallying After Eli Lilly Deal?](https://longbridge.com/en/news/296113651.md) - [Elyxium Wealth LLC Has $7.30 Million Position in Eli Lilly and Company $LLY](https://longbridge.com/en/news/296017075.md) - [Eli Lilly EVP, international president Patrik Jonsson disposes of 6,500 shares worth $7.64 million](https://longbridge.com/en/news/296266483.md) - [Eli Lilly Is Building a Weight Loss Drug for Every Kind of Patient](https://longbridge.com/en/news/296005917.md) - [Community Financial Services Group LLC Acquires 1,774 Shares of Eli Lilly and Company $LLY](https://longbridge.com/en/news/295504105.md)